• In late January 2026, Thermo Fisher Scientific reported fourth-quarter 2025 results showing sales of US$12.22 billion and net income of US$1.96 billion, with both basic and diluted EPS from continuing operations increasing versus the prior year.
• For 2025, the company delivered higher full-year sales of US$44.56 billion and net income of US$6.70 billion, supported by new product launches, acquisitions and strong pharma, biotech and diagnostics demand that reinforced confidence in its outlook.
• We’ll now examine how Thermo Fisher’s stronger-than-expected 2025 earnings, underpinned by robust pharma and biotech demand, shape its investment narrative.

These 14 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

What Is Thermo Fisher Scientific's Investment Narrative?

To own Thermo Fisher today, you need to believe that its broad toolkit for pharma, biotech and diagnostics will keep attracting demand even as some end markets wobble. The latest 2025 results support that view: higher sales and earnings, strong cash generation, and continued investment in new instruments and acquisitions. At the same time, management’s 2026 outlook, the planned US$9 billion Clario deal, and the Franklin, Massachusetts plant closure underline the near term trade off between growth initiatives and margin and integration risk. The recent share price pullback after cautious guidance suggests the earnings beat has not fully offset concerns around pressured academic and government spending, leadership changes and elevated valuation. For now, the quarter looks incrementally positive, but it does not completely remove the key risks.

However, funding pressure on academic and government customers remains a risk investors should not ignore. Thermo Fisher Scientific's share price has been on the slide but might be up to 10% below fair value. Find out if it's a bargain.

Exploring Other Perspectives

Twelve Simply Wall St Community fair value views span roughly US$409 to US$662 per share, showing wide disagreement. Set that against Thermo Fisher’s cautious 2026 guidance and funding risk to see why opinions diverge so sharply.

Explore 12 other fair value estimates on Thermo Fisher Scientific - why the stock might be worth as much as 14% more than the current price!

Build Your Own Thermo Fisher Scientific Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Thermo Fisher Scientific research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Thermo Fisher Scientific research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Thermo Fisher Scientific's overall financial health at a glance.

Want Some Alternatives?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Outshine the giants: these 24 early-stage AI stocks could fund your retirement.
• Find companies with promising cash flow potential yet trading below their fair value.
• Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.